For more than two decades, a 45-year-old woman's nights were crowded with problems that rarely show up together. She ate while asleep, had night terrors, acted out frightening dreams, repeatedly stopped breathing during sleep, lived on a delayed body clock, and fought heavy sleepiness during the day.
A case report in the journal Sleep Medicine documents the cluster: mixed sleep apnea, night terrors, sleep-related eating disorder, nightmare disorder with dream-enactment behavior, excessive daytime sleepiness, and delayed sleep-wake phase disorder. It also describes a notable turn. Her sleep-eating disorder resolved during a period that included substantial weight loss and treatment with a GLP-1 receptor agonist, the drug class that includes widely used diabetes and weight-loss medications.
The authors are explicit that causality cannot be established. The timing is a clue, not proof, and other recent case reports suggest these drugs can push sleep behavior in more than one direction.
Six Sleep Problems Stacked in One Patient
Each of her conditions disrupts sleep differently. Mixed sleep apnea combines features of obstructive apnea, in which the airway collapses, and central apnea, in which the brain briefly fails to signal a breath. Night terrors are episodes of intense fear that erupt from deep non-REM sleep, usually with little memory afterward. Delayed sleep-wake phase disorder pushes the internal clock later, making it hard to fall asleep and wake at conventional times.
Sleep-related eating disorder may be the most unsettling. Sleep specialists writing in Psychiatric Times describe it as recurrent, involuntary eating and drinking during arousals from non-REM sleep, usually with partial or no awareness and limited or no recall. It differs from night eating syndrome, in which people eat while awake and remember it afterward. The same authors note that sleep eating can appear alongside several other parasomnias in one person and that the sleep drug zolpidem has been associated with it, prompting FDA warnings.
Clinicians have long seen these behaviors cluster. In a 2022 case report of another 45-year-old woman who sleepwalked, ate, and smoked in her sleep, the authors urged clinicians to ask about other parasomnias whenever a patient reports one.
Sleep Eating Faded as Her Weight Fell
The new report cannot separate the weight loss from the medication, and the authors do not claim the drug caused the change.
One plausible indirect route runs through breathing. Sleep-related eating often coexists with other sleep disorders, including obstructive sleep apnea, and interrupted breathing fragments sleep. Weight loss can ease apnea. In December 2024, the FDA approved Zepbound (tirzepatide) as the first medication for moderate to severe obstructive sleep apnea in adults with obesity, noting that the improvement in breathing is likely related to weight loss.
Weight loss alone does not always end sleep eating, though. In the 2022 case, bariatric surgery resolved the woman's mild sleep apnea, but her three parasomnias were controlled with nightly topiramate and returned whenever the drug was stopped.
A report published in January adds another data point. Clinicians described a 40-year-old woman whose sleep eating improved on tirzepatide, a drug that acts on both GLP-1 and GIP receptors, after topiramate and zonisamide had not helped. She reported only rare episodes over six months. Even so, those authors stressed that the role of GLP-1 drugs in eating disorders remains unclear.
The Same Drug Class Has Been Linked to Night Terrors
Evidence also points the other way. An abstract in the SLEEP journal's 2026 meeting supplement described a 42-year-old woman with obesity and a remote history of childhood parasomnia who developed night terrors after starting semaglutide. The episodes grew more frequent as her dose increased.
When her dose was lowered, the night terrors eased and resolved within 10 days. When she inadvertently returned to the higher dose, they came back within 48 hours and resolved again after another reduction.
The author suggested that GLP-1 drugs might affect arousal regulation or the stability of deep sleep in predisposed people and urged clinicians to watch for new sleep behaviors as use of the drugs expands.
Taken together, these single-patient reports suggest the relationship between GLP-1 medications and parasomnias is worth studying but far from understood. Case reports flag patterns clinicians might otherwise miss. They cannot show whether an effect is common, predictable, or caused by the treatment.
A Signal for Doctors, Not a Treatment Plan
For people who wake up to empty wrappers or are told they scream, walk, or act out dreams at night, the practical point is that these behaviors often travel with other sleep problems that can be diagnosed.
Anyone noticing unexplained nighttime eating, dream enactment, or loud snoring with pauses in breathing should talk with a clinician, who may recommend a sleep evaluation and a review of current medications, including sedative sleep aids.
The report does not support using GLP-1 drugs to treat sleep eating. No one should start, stop, or adjust a medication based on a single case.
Key Questions Answered
What did doctors report?
A 45-year-old woman had six overlapping sleep problems lasting more than two decades, including sleep apnea, night terrors, sleep eating, and dream enactment.
What is sleep-related eating disorder?
It is a parasomnia involving involuntary eating or drinking during arousals from non-REM sleep, usually with little or no memory of the episode.
Did a GLP-1 drug cure her sleep eating?
That was not shown. The eating resolved during a period that included weight loss and GLP-1 treatment, and the authors say causality cannot be established.
Can GLP-1 drugs worsen sleep behaviors?
One 2026 abstract described night terrors that tracked a woman's semaglutide dose, easing when it was lowered and returning when it was raised. The evidence is limited to individual reports.
What should someone with strange nighttime behaviors do?
Talk with a clinician about a sleep evaluation and review current medications, without changing any prescription on their own.
